Literature DB >> 16828941

An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinated people living in a nursing home.

A M Iorio1, M Neri, E Lepri, B Camilloni, M Basileo, N Sigismondi, C Fabiani, L Calzoletti, S Puzelli, I Donatelli.   

Abstract

This study examined the antibody response against the three vaccine antigens and the epidemic A/H3N2 drift variant (A/California) and the prevention of laboratory diagnosed influenza infections in a group of elderly institutionalized people vaccinated with the 2004/2005 influenza vaccine. Antibody titres were measured by hemagglutination inhibition (HI) in sera collected before and 1 month after vaccination. Laboratory diagnosis was done examining throat swabs (RT-PCR or MDCK cell culture) or by serology (seroconversion comparing HI titres in sera collected 1 and 5 months after vaccination). Results obtained showed that influenza vaccination induced an adequate immune response against the three vaccine antigens and the epidemic A/H3N2 variant, however it was not capable of preventing an influenza outbreak due to the new A/H3N2 (A/California) variant.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16828941     DOI: 10.1016/j.vaccine.2006.05.037

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).

Authors:  Luzhao Feng; Peng Yang; Tao Zhang; Juan Yang; Chuanxi Fu; Ying Qin; Yi Zhang; Chunna Ma; Zhaoqiu Liu; Quanyi Wang; Genming Zhao; Hongjie Yu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.

Authors:  Barbara Camilloni; Michela Basileo; Stefano Valente; Emilia Nunzi; Anna Maria Iorio
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Recommendations on the use of MF59-Adjuvanted Trivalent Influenza Vaccine (Fluad®): Supplemental Statement of Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-10-21

4.  Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs.

Authors:  Noriko Kishida; Seiichiro Fujisaki; Masaru Yokoyama; Hironori Sato; Reiko Saito; Hideyuki Ikematsu; Hong Xu; Emi Takashita; Masato Tashiro; Shinichi Takao; Takuya Yano; Tomoko Suga; Chiharu Kawakami; Miwako Yamamoto; Keiko Kajiyama; Hiroyuki Saito; Shin'ichi Shimada; Sumi Watanabe; Satomi Aoki; Katsuya Taira; Miyako Kon; Jih-Hui Lin; Takato Odagiri
Journal:  Clin Vaccine Immunol       Date:  2012-04-04

5.  Surveillance of lower respiratory tract infections outbreaks in nursing homes in France.

Authors:  Sophie Vaux; Isabelle Poujol; Isabelle Bonmarin; Daniel Lévy-Bruhl; Jean-Claude Desenclos
Journal:  Eur J Epidemiol       Date:  2009-02-07       Impact factor: 8.082

6.  Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection.

Authors:  Dimitrios G Koutsonanos; Elena V Vassilieva; Anastasia Stavropoulou; Vladimir G Zarnitsyn; E Stein Esser; Misha T Taherbhai; Mark R Prausnitz; Richard W Compans; Ioanna Skountzou
Journal:  Sci Rep       Date:  2012-04-12       Impact factor: 4.379

7.  A benchmark dataset of protein antigens for antigenicity measurement.

Authors:  Tianyi Qiu; Jingxuan Qiu; Yiyan Yang; Lu Zhang; Tiantian Mao; Xiaoyan Zhang; Jianqing Xu; Zhiwei Cao
Journal:  Sci Data       Date:  2020-07-06       Impact factor: 6.444

8.  Influence of prior influenza vaccination on antibody and B-cell responses.

Authors:  Sanae Sasaki; Xiao-Song He; Tyson H Holmes; Cornelia L Dekker; George W Kemble; Ann M Arvin; Harry B Greenberg
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.